Mangoceuticals' patented mgx-0024 delivers 100% respiratory survival in poultry studies signaling strong potential defense against spread of avian flu

Dallas, tx, may 27, 2025 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) ("mangoceuticals" or the "company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands mangorx and peachesrx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as “mgx-0024”. the field studies were conducted by solice international at duraiswamy farm in palladam, tamil nadu, india. these studies, targeting respiratory diseases in chickens, like newcastle disease and chronic respiratory disease (crd), showed mgx-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses in a large-scale trial, offering a promising solution for poultry health and avian flu defense.
MGRX Ratings Summary
MGRX Quant Ranking